LYMPHOMAS

Results from JACKPOT8 presented during the 2022 EHA Congress show that golidocitnib has encouraging anti-tumor efficacy and tolerable safety in patients with relapsed or refractory peripheral T-cell lymphoma.

Data from ANTLER presented during the 2022 EHA Congress show initial findings of CB-010 in patients with relapsed or refractory B-cell non-Hodgkin lymphoma.

At the 2022 ASCO Annual Meeting, the primary analysis of the phase 2 PILOT study showed the durability and feasibility of lisocabtagene maraleucel as second-line therapy in certain patients with large B-cell lymphoma.

According to Michael Dickinson, MBBS, glofitamab is a highly active drug. The agent showed durable response in patients with heavily pretreated large B-cell lymphoma.

Therapy with brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine lead to a significant reduction in the risk of death vs doxorubicin, bleomycin, vinblastine, and dacarbazine, in patients with previously untreated stage III/IV classical Hodgkin lymphoma.

Treatment with sugemalimab shown to be well-tolerated and have a consistent safety profile to other studies, according to results of the GEMSTONE-201 trial.

The FDA has withdrawn its approval for the umbralisib, which had previously been approved for marginal zone lymphoma and follicular lymphoma.

In an interview with Targeted Oncology, Manali Kamdar, MD, discussed the current relapsed/refractory B-cell non-Hodgkin lymphoma space, along with data from the phase 1 clinical trial of an anti-CD19 CAR T-cell product for these patients.

In relapse/refractory follicular lymphoma, promising results have been observed with PI3K inhibitors and are encouraging because of the less than optimal outcome associated with Bruton's tyrosine kinase inhibitors.

The use of single-agent odronextamab demonstrated a manageable safety profile and promising preliminary activity in heavily pretreated patients with B-cell non-Hodgkin lymphoma.

Looking at 4 CAR T-cell agents for the treatment of large B-cell lymphoma, a systematic review and analysis showed that these therapies do not appear to increase the risk of cytokine release syndrome or immune effector cell–associated neurotoxicity syndrome.

Continued benefit of axicabtagene ciloleucel in patients with relapse/refractory indolent non-Hodgkin lymphoma was observed in the phase 2 ZUMA-5 clinical trial.

In patients with relapsed/refractory large B-cell lymphoma, the chimeric antigen receptor T-cell agent, lisocabtagene maraleucel demonstrated durable responses.

According to a long-term analysis of the ZUMA-1 study, the overall survival rate yielded by axicabtagene ciloleucel may support 1- and 2-year event-free survival as a surrogate end point in relapsed/refractory large B-cell lymphoma.

Frontline treatment with axicabtagene ciloleucel demonstrated a high rate of rapid and durable responses in patients with high-risk large B-cell lymphoma in the phase 2 ZUMA-12 study.

Ann LaCasce, MD, MMSc, discussed how the landscape for patients with indolent B-cell lymphomas has changed positively over the past decade.

With a voluntary partial clinical hold in place, patients who were already enrolled to the TakeAim Lymphoma study and deriving benefit from emavusertib can continue treatment at the dose of 300 mg twice daily or lower.

CCR7-positive and CD45RA-positive T cells that expressed CD27 and CD28 appear to be associated with all efficacy metrics, including durability or response, according to an analysis of the ZUMA-7 clinical trial.

The bispecific antibody therapy AMF13 combined with preactivated and expanded natural killer cells showed encouraging activity in patients with heavily pretreated lymphoma.

Matthew J. Matasar, MD, discusses the ways to improve on the combination of R-CHOP in patients with diffuse large B-Cell lymphoma.

Results from the phase 3 I/ONTAK trial demonstrated anti-tumor activity in the treatment of persistent or recurrent CTCL

FDA fast track designation has been granted to a novel agent, DT2216, for the treatment of patient with relapsed or refractory peripheral T-cell lymphoma and cutaneous T-cell lymphoma.

Chimeric antigen receptor expansion by day 10 could be an early biomarker to predict response and survival in patients with B-cell lymphoma.

The FDA discouraged marketing authorization for zandelisib based data from the phase 2 TIDAL study which examined the PI3K inhibitor in subjects with relapsed/refractory follicular lymphoma or marginal zone lymphoma.

Lisocabtagene maraleucel has demonstrated benefit to event-free survival for patients with relapsed/refractory large B-cell lymphoma.